Zynext Ventures invests in Illexcor Therapeutics to advance novel oral therapy for sickle cell disease
Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD
Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD
The MDR certification reafirms that these products meet the highest safety, quality, and regulatory standards
Announces Rs. 317 crore investment in new recycling plant
Overall investment in the US facility is estimated around US$50 million
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Amaran Biotech boasts Taiwan’s first fully automated robotic aseptic filling line, offering high-quality and low-waste filling solutions for high-value pharmaceuticals
The recent EU approval of MBL's plant has opened new avenues to explore such opportunities
This termination of Agreement will not have any significant impact on the company and/or its subsidiaries or its financials
Subscribe To Our Newsletter & Stay Updated